Abstract: Genetic studies have demonstrated that osteoclasts are essential for focal erosion of bone and cartilage as a consequence of chronic pro-inflammatory cytokine production (TNF, IL-1) in inflammatory arthritis. In these inflamed joints, mature osteoclasts differentiate from circulating osteoclast precursors (OCPs) in response to local increased production of RANKL and pro-inflammatory cytokines. Once activated to resorb calcified matrix, these osteoclasts have a short lifespan (days), and must be continually replaced by bone marrow derived OCPs to achieve focal erosions. Therefore, the peripheral blood OCP frequency may directly determine the severity of bone erosion around inflamed joints. Based on the remarkable advances in our knowledge of osteoclast biology, investigators have been able to model the molecular events that control temporal and spatial regulation of osteoclastogenesis in vivo. Here we review the results of these pre-clinical and clinical studies and provide model of pathogenesis in which pro-inflammatory cytokines produced in the joint feedback on the bone marrow to produce and release elevated numbers of OCP into the circulation, which then home to the inflamed joint. Understanding the regulation of OCP generation and mobilization will provide a new strategy for development of drug targets in the treatment of inflammatory arthritis and other disorders associated with elevated peripheral OCP/myeloid progenitors.
INTRODUCTION
current progress in OCPs studies in inflammatory arthritis. Since osteoclasts are the primary effector cells for bone resorption, some of these mechanisms are likely to be conserved in other erosive diseases associated with increased local bone erosion, such as tumor metastasized to bone and periodontal disease.
In postnatal life, osteoclastogenesis occurs normally on the bone surface within the bone marrow cavity. Physiologically, osteoclasts remove aged or damaged bone, which is then replaced by osteoblasts, to maintain calcium homeostasis and skeletal integrity. Under disease conditions such as rheumatoid arthritis (RA) or psoriatic arthritis (PsA), osteoclasts mediate a bi-directional attack on cortical bone to cause abnormal bone resorption, which leads to irreversible joint damage, osteoporotic fractures, and bone pain [1] . Osteoclastogenesis requires the differentiation of osteoclast precursors (OCPs) to mature osteoclasts with the help of M-CSF and RANKL, two essential cytokines for osteoclast formation. OCPs are generated in the bone marrow from hematopoietic stem cells. In the case of inside-out erosion, OCPs differentiate in response to RANKL produced by stromal cells and produce cutting cones that traverse the subchondral bone [2] . Outside-in, peri-articular erosions are mediated by osteoclasts that differentiate in response to RANKL produced by T-cells and fibroblasts in the synovial lining of the pannus [2] [3] [4] [5] . Recent findings that increased peripheral OCPs in blood of arthritic animals and patients suggest that at least one of the sources of OCPs under these conditions, particularly in outside-in erosion, is from the blood, which involve the release of OCPs from the bone marrow to the circulation, and then to the inflamed joints [2, 6, 7] . Thus, understanding the generation, mobilization and migration of OCPs may represent a new regulatory mechanism for osteoclastogenesis. This review will focus on
OSTEOCLAST PRECURSORS IN THE BONE MARROW

Origins
During embryonic development, hematopoiesis first occurs in the yolk sac. One early study has reported that TRAP + multinucleated cell potential occurs as early as at embryonic day 8.5 in the yolk sac of the mouse embryo [8] . Recently, we have confirmed this finding and demonstrated that osteoclasts can be derived from embryonic day 7.25 yolk sac cells in the presence of M-CSF and RANKL, suggesting that these are the earliest OCPs (Palis & Xing, unpublished data). Late in the fetal life, hematopoietic activity moves to the fetal liver and then initiates in the bone marrow, which becomes the predominant site of hematopoiesis shortly after birth.
In the bone marrow, hematopoietic stem cells give rise to two kinds of multi-potent lineage progenitors: common lymphoid progenitors (CLPs) and myeloid progenitors (CMPs), based on their distinguished surface markers (mainly IL-7 receptor), gene expression file and clonogenic potency [9] (Fig. 1) . CLPs give rise to B, T lymphocytes and NK cells. Under certain conditions, early stage B cell precursors, B220 + pro-B cells, can trans-differentiae to osteoclasts in the presence of M-CSF and RANKL [10] . For instance, in Pax5 knockout mice, B lymphocytogenesis is halted at the pro-B stage and osteoclastogenesis is elevated, Fig. (1) . Osteoclastogenesis from hematopoietic stem cells and essential genes involved in this process. HSC: hematopoietic stem cell, CLP: common lymphoid progenitor, CMP: common myeloid progenitor, GMP: granulocyte-macrophage progenitor, MEP: megakaryocyte-erythrocyte progenitor, MODP: macrophage-osteoclast-dendritic cell progenitor.
indicating that B cells and osteoclasts may have a common ancestor whose fate is determined by transcription factor Pax5 [11] . Other lymphocytes, including mature T and B cells, affect osteoclastogenesis indirectly by producing RANKL or OPG, even though they do not have osteoclast forming potency [5, 12, 13] . difficult because differentiation is a continuous process and the surface markers are shared at a lot of time. Nevertheless, experimental data have demonstrated that CD11b + /Gr-1 hi (granulocyte) and B220 + /IgM + (B lymphocyte) cells, which harbor the surface markers of mature cells, cannot give rise to osteoclasts following treatment with M-CSF and RANKL [17, 19] . CMPs, dependent on their Epo receptor status, can be further divided into two committed lineage progenitors: megakaryocyte/erythrocyte progenitors and granulocyte/ macrophage progenitors (GMPs). To date there is no evidence that megakaryocyte/erythrocyte progenitors have osteoclastic potential. However, megakaryocytes may indirectly affect osteoclast function by producing TGFβ and PDGF, which are important regulators of osteoclastogenesis [14] . GMPs are further differentiated to mature granulocytes (CD11b + /Gr-1 hi ) and MODPs, macrophage/osteoclast/ dendritic cell precursors (CD11b + /Gr-1 -/lo ). Almost all MODPs are able to give rise to osteoclasts at some stages during their differentiation. CD11c is a cell surface marker for dendritic cells and F4/80 is a macrophage marker. Interestingly, under certain conditions, both CD11c + dendritic cells and F4/80 + macrophages can transdifferentiate to osteoclasts [15] [16] [17] . The direction of transdifferentiation among late stage myeloid precursors is largely dependent on the local expression profile of cytokines, which emphases the importance of microenvironment in determining the fate of myeloid precursors. Similarly, early myeloid precursors (CD11b + /c-Fms -) can be induced to express a B-cell-like phenotype (B220 + ) when they are cultured on a stromal/osteoblast cell line and treated with IL-7 [18] . To determine at which stage a progenitor cell loses its multi-lineage potency for differentiation is relatively
Biologic Features
Mature osteoclasts are characterized by positive tartrateresistant acid phosphatase (TRAP) staining. TRAP is highly expressed by mature osteoclasts and is a landmark for identifying osteoclasts in vivo and in vitro. Unfortunately, OCPs are TRAP negative and lack specific cell surface markers, which makes study of the regulation of OCPs difficult. To date, several groups including our own have used a comprehensive immuno-phenotyping, flow sorting, colony forming and osteoclastogenesis assay to identify osteoclast precursors. The criteria of OCPs include that they 1) belong to hematopoeitic cells (c-Kit + ); 2) harbor the cell surface markers for myeloid lineage precursors, such as CD11b and c-Fms; 3) do not express specific surface markers for mature cells; 4) form CFU-GM colonies in the presence of GM-CSF and M-CSF in semi-sold agar cultures, and 5) differentiae to TRAP + cells and have bone resorbing ability in liquid cultures with M-CSF and RANKL [6, 18, 20] .
Using these criteria, we and others have demonstrated that bone marrow OCPs have the following features: 1) both CD11b + /Gr-1 -/lo and CD11b -/Gr-1 -/lo cells can give rise to osteoclasts in vitro with M-CSF and RANKL, but the CD11b + /Gr-1 -/lo cells have higher osteoclast forming potential; 2) within the CD11b + population, both c-Fms + and c-Fms -cells form osteoclasts; 3) it is a generally accepted notion that CD11b + /Gr-1 -/lo /c-Fms -cells are the early stage precursors and CD11b + /Gr-1 -/lo /c-Fms + cells are the late stage OCPs [6] ; 4) the CD11b + /Gr-1 -/lo /c-Fms -cells are highly proliferative; and 5) in liquid cultures with M-CSF, the majority of bone marrow cells attach to the culture plate and become CD11b + /Gr-1 -/lo /c-Fms + late stage OCPs while early stage CD11b + /Gr-1 -/lo/ c-Fms -OCPs reside in the non-adherent fraction [6, 18, 20] . adolescent growth and bone remodeling in adult life. The mice with defective osteoclastogenesis before birth are osteopetrotic and their bone marrow cavity is filled with bone matrix, leading to retardation in bone growth and extramedullar hematopoiesis. Many types of mice with various genetic modifications belong to this category, such as mice that have deficient in genes for PU.1, c-Fms, RANKL, RANK, NF-κB, c-Fos or c-Src [21, 22] . Bone remodeling is an active repair process which is executed by osteoclasts to remove the damaged and aged bone, and is followed by osteoblastic bone formation. The balance between osteoclastic bone resorption and osteoblastic bone formation determines the direction of gain or loss of bone mass, which is regulated by systemic hormones and cytokines. Although OCPs themselves do not have bone-resorbing capacity, the number of OCPs in circulation is perhaps directly associated with the numbers of mature osteoclasts at any given site of resorption. For instance, PU.1-/-or c-Fms-/-mice have significantly reduced number of precursors for osteoclasts and macrophages and they develop severe osteopetrosis [26, 29] . However, the relationship between OCP numbers and the degree of bone resorption by mature osteoclasts at a give time needs to be investigated in detail.
Regulation
Differentiation of CD11b + /Gr-1 -/lo /c-Fms + late stage OCPs from multi-potent myeloid lineage progenitors involves a highly ordered series of events involving differentiation, proliferation and anti-apoptotic signals, which are regulated by multiple factors. Of note, genetic deletion of PU.1, c-Fms, M-CSF, c-Fos, NF-κB, RANK and RANKL all lead to lack of TRAP + mature osteoclasts in vivo [21, 22] . Among them, M-CSF and RANKL are the ligand for c-Fms and RANK. They are produced by stromal/osteoblasts, which belong to the cells in the mesenchymal lineage. c-Fos, NF-κB or RANK knockout mice have relatively normal numbers of CD11b + /Gr-1 -/lo MODPs, suggesting that the blockade in osteoclastogenesis in these mice is at the stage beyond the CD11b + /Gr-1 -/lo /cFms + cells, and c-Fos, NF-κB or RANK are not essential for OCP genesis [23] [24] [25] .
OSTEOCLAST PRECURSORS IN THE PERIPHERAL BLOOD AND SPLEEN
Besides bone marrow, cells from many other sources can also form mature osteoclasts when they are cultured in vitro with RANKL and M-CSF, such as cells from peripheral blood, spleen, liver and lung [21, 22] . Among them, it is important to study blood OCPs further because of their potentially significant clinical impact. Unfortunately, there have been few studies of OCPs in bone diseases [34, 35] , in part because of the lack of unique markers to identify them. c-Fms is the receptor for M-CSF. c-Fms-/-mice have no TRAP + osteoclasts, reduced CD11b + /Gr-1 -/lo MODPs, and normal number of Gr-1 hi granulocytes, indicating that c-Fms expression by GMPs is essential for MODP development [26] . The transcription of c-Fms is regulated by members of the Ets family. In the c-Fms promoter, there are several Ets binding sites. Ets family members PU.1, Ets 1, and 2 all activate c-Fms promoter activities in vitro. However, PU.1 and Ets 2 have a more direct influence on cells in the myeloid lineage because Ets 1 expression is very low or undetectable in macrophages and osteoclasts [27, 28] . PU.1 is expressed in all types of myeloid cells and Blymphocytes, and deletion of PU.1 leads to a reduction in the number of precursors in both lineages and failure of osteoclast formation [29, 30] . In contrast, Ets 2 is only expressed in late stage myeloid cells and its expression is rapidly up-regulated upon induction of macrophage differentiation from progenitors. Recently, increased expression of Ets protein has been observed in blood and synovium samples from arthritic animals and patients, suggesting that inflammatory cytokines, such as TNF, may stimulate the expression of Ets members [31] [32] [33] . Thus, it is possible that in inflammatory erosive arthritis or other bone diseases associated with increased cytokine expression, the expression of Ets members is elevated leading to increased OCP differentiation.
Based on their different location and function, it is expected that blood OCPs differ from marrow OCPs. We have started to compare bone marrow, blood and spleen derived OCPs in mice and found that: 1) both marrow CD11b + /Gr-1 -/lo and CD11b -/Gr-1 -/lo cells form osteoclasts in vitro, while in blood and spleen only CD11b + /Gr-1 -/lo , but not CD11b -/Gr-1 -cells form osteoclasts; 2) in spleen, both CD11b + /c-Fms + and CD11b + /c-Fms -cells form osteoclasts [6] ; and 3) unlike bone marrow, the blood CD11b + /Gr-1 -/lo cells do not proliferate and their gene expression profile differs significantly from that of the bone marrow. These findings are consistent with reports on blood vs bone marrow CD34 + cells [36, 37] .
THE MOBILIZATION OF OSTEOCLAST PRECURSORS
Like other hematopoietic cells, OCPs are generated in the bone marrow, released into the circulation, and home to their final destination where they differentiate into osteoclasts. Compared to our understanding of OCP generation in the bone marrow, little is known about how these OCPs are released and what their specific phenotype is at that time. However, since osteoclasts share the same progenitor cell as macrophages and dendritic cells, which have been studied, it is inferred that OCP mobilization in vivo also involves at least two major steps: release into the blood and homing
Bone resorption
The critical function of a mature osteoclast is to resorb bone. Osteoclast-mediated bone resorption is essential for normal bone modeling during embryonic development and from blood to peripheral tissues where the immature OCPs finally differentiate into mature osteoclasts.
osteoclast activation and survival in vivo. RANK mRNA is expressed by many cells, but the expression of RANK protein is only detected on the surface of osteoclasts, T cells, and dendritic cells [21, 22, 24] . Therefore, most studies have focused on those cells. Recently, RANK protein expression was identified on the surface of human peripheral blood monocytes. RANKL stimulates the migration of these cells, which can be blocked by OPG or inhibitors for PI3-kinase, phosphodiesterase, and Src kinase [46, 47] . These findings suggest a new mechanism for RANKL, which is produced at excess amount by synovial fibroblasts from RA patients and CD4 + and CD8 + T lymphocytes in RA synovium. Because inflammatory macrophages, dendritic cells and osteoclasts can be derived from peripheral blood monocytes, RANKLinduced monocyte migration may contribute to bone loss in arthritis. Since RANKL does not have chemotactic properties on murine primary bone marrow monocytes or Raw 264.7 bone marrow derived monocyte cell line [43] , whether this is due to the species difference or the cell origin difference needs to be investigated in the future.
The mobilization of hematopoietic stem and progenitor cells is a very complicated process, which involves adhesion molecules, proteolytic enzymes, cytokines, stromal cells and chemokines [38, 39] . The mechanisms that regulate cell release from the bone marrow into the blood are largely undefined. To enter the circulation, cells must migrate towards a chemokine gradient and across the vascular barrier composed of endothelial cells, a basement membrane, and a layer of adventitial cells. Using human blood monocytes as a source of OCPs and bone marrow derived endothelial cell line as endothelium layer, McGowan et al. found that OCPs can adhere to endothelium. Treatment of the endothelium with IL-1 or TNF depletes all the OCPs in the PBMC population, suggesting that these cytokines stimulate the transendothelial mobilization of OCPs [40] .
Small chemotactic cytokines, chemokines, function as key mediators controlling the mobilized recruitment and targeted homing of circulating cells to particular organs. Among 70 or more chemokines, stromal-derived factor (SDF-1) is the most powerful retention signal in the bone marrow for hematopoietic stem and progenitor cells. SDF-1 knockout mice are embryonic lethal due to impaired bone marrow lymphoid and myeloid hematopoiesis [41] . Most other chemokines are redundant and have some cell type specificity. In general, chemokines are divided into A and B categories. The A chemokine subfamily members, including IL-8, chemoattract and activate neurophils and Tlymphocytes, but not monocytes. Many of the B chemokines, such as macrophage inflammatory protein-1α (MIP-1α)/CCL3, RANTES/CCL5, and MCP-1/CCL2, act as chemoattractants and activators of monocytes, but not neutrophils.
OSTEOCLAST PRECURSORS AND CHRONIC INFLAMMATORY ARTHRITIS
Lessons from Transgenic Mice
Although several cells including macrophages, have been proposed to have the ability to resorb bone in variety experimental systems, recent genetic studies have clearly demonstrated osteoclasts as the primary effector cells responsible for bone and cartilage damage in RA. Both cFos-/-or RANK-/-x TNF-Tg double transgenic mice have no osteoclasts or bone erosion in spite of persistent joint inflammation [48, 49] . Thus, targeting osteoclasts is a new strategy to treat or prevent bone and cartilage destruction in arthritic joints and osteoporosis associated with it. Using M-CSF-dependent bone marrow cells, Raw 264.7 macrophages, and human PBMC as source of OCPs, in vitro chemotactic or migration assay demonstrates that OCPs migrate along chemokine gradients. Of the many chemokines tested in different publications, SDF-1, MIP-1α, RANTES and CKβ-8 have chemotactic effects on OCPs [42, 43] . SDF-1, MIP-1α, and RANTES are highly produced by synoviocytes, T cells, and macrophage/monocytes infiltrating the synovial tissues in RA. It is conceivable that these chemokines will attract circulating OCPs or even OCPs from the subchondral bone.
Our studies of OCPs were initiated based on an observation showing a significantly increase in CD11b + splenocytes in TNF transgenic (TNF-Tg) mice, a widely used animal model of RA [6] . This increase was associated with circulating TNF levels and could be blocked by anti-TNF therapy. The proliferation and apoptosis rate of spleen CD11b + cells were compatible between TNF-Tg mice and wild type littermates, and injection of TNF into wild-type mice caused the similar increase in CD11b + cells in the blood and spleen, suggesting that systemic TNF may affect the distribution of OCPs and increase the OCP pool in the peripheral. To support this hypothesis, we have demonstrated that TNF stimulates the proliferation of bone marrow CD11b + /Gr-1 -/lo /c-Fms + OCPs and sequentially increases their numbers in the blood. Currently, it is not known whether TNF actively promotes OCP mobilization or whether there is a chemokine gradient existing among bone marrow, blood and inflamed joints, which attracts OCPs leaving bone marrow through blood to joints. Dramatically increased SDF-1 protein expression in joint specimen of RA patients and arthritis animals suggests a chemokine gradient between inflamed synovium and bone marrow or peripheral blood [50, 51] .
Recently, Oba Y. et al. used a PCR selective, cDNA subtraction approach, to screen a cDNA library from mature osteoclasts and OCPs and found that eosinophil chemotactic factor-L promotes the migration of OCPs in vitro. Like MIP-1α, it also stimulates osteoclastogenesis and bone resorbing activity of osteoclasts in the presence of 1, 25(OH) 2 vitamin D 3 . Interesting, eosinophil chemotactic factor-L does not affect RANKL production by stromal cells, but its neutralizing antibody significantly inhibits RANKL or 1, 25(OH) 2 vitamin D 3 -induced osteoclast formation [44] . Eosinophil chemotactic factor-L is highly expressed in RA synovium and it may play a role in regulating OCP migration to inflamed joints [45] .
In an adjuvant-induced arthritis model, culturing bone marrow cells from the diaphyseal bone of arthritic rats results in decreased osteoclast formation while culturing RANK, receptor for RANKL, mediates intracellular signals obligatory for osteoclastogenesis as well as those isolated from the distal tibia near the inflamed joints gives rise to remarkable increased osteoclasts, suggesting an uneven distribution of OCPs. Consistent with this, MIP-α expression is significantly increased in macrophages localized at the distal tibia of arthritic rats and MIP-α has a strong chemotactic effect for OCPs in vitro. These findings indicate that migration of OCPs within the bone marrow toward to MIP-α gradient may account for inside-out osteoclast-mediated bone and cartilage erosion [52, 53] . patients with RA have peripheral blood monocytosis and that the mononuclear cell population in RA patients contains higher numbers of monocytes. Subsequently, accelerated generation of CD14 + monocyte-lineage cells from the bone marrow of RA patients is observed [54] . Interestingly, the increased CD14 + cells can be reversed by treatment of patients with disease-modifying antirheumatic drug, Methotrexate [55] . Bone marrow stromal cells from RA patients fail to support normal hematopoiesis and produce abnormally high amounts of TNF. Anti-TNF therapy reverse all these abnormality, suggesting that TNF, at lease, is one of the contributors to the alternation [56] . Based on the findings from TNF-Tg mice in which TNF stimulates OCP proliferation and differentiation from c-Fms -early OCPs to c-Fms + late OCPs, it is interesting to see whether TNF stimulates the conversion of CD14 -cell to CD14 + cells or whether TNF stimulates the proliferation of CD14 + cells in RA patients.
Whether or not increased peripheral OCP frequency also occurs in other animal models of arthritis has yet to be formally tested. However, De Klerck et al. have shown a significant increase of CD11b + OCPs in spleen in interferon gamma receptor knockout mice with collagen II-induced arthritis [7] . Thus, further studies such as the blood OCP frequency and its relationship to the severity of cartilage and bone erosion in various animal models of arthritis are needed to explore the possibility that increased peripheral OCPs may be a common mechanism for bone erosion in RA.
In order to assess the clinical importance of OCP frequency in PBMCs, we demonstrated that the number of OCPs (CD11b + /CD14 + ) was significantly increased in blood from patients with psoriatic arthritis (PsA). Etanercept administration suppresses the number of circulating OCPs, which occurs as early as 2 weeks after anti-TNF therapy. A significantly correlation was noted between the erosion
Lessons from Clinical Studies
RA is a systemic autoimmune disease and it not only affects the joints but also other systems including bone marrow. It has be a long time observation that 30% of Fig. (2) . Proposed model of osteoclast precursor generation, mobilization and homing in erosive arthritis. We propose that during chronic inflammation, elevated systemic cytokines, such as TNF, mediate focal bone loss through 3 mechanisms: 1) increasing OCP proliferation in the bone marrow to produce more OCPs; 2) increasing chemokine production by cells in the inflamed synovium to generate a chemokine gradient among bone marrow, blood and joints, and 3) changing blood vessel endothelium to enhance the trans-endothelium mobilization of OCPs toward the chemokine gradient. The end effect is increased OCPs in the inflamed joints, which differentiate to mature osteoclasts in response to over-produced RANKL and other cytokines to cause bone and cartilage erosion.
scores and the OCP frequency, suggesting that the OCP frequency may be used as a biomarker to help to determine which PsA patients are at greater risk for bone erosion [2] . Recently we compared the OCP frequency in PBMC from patients with RA, PsA or Crohn's disease (CD) [57] . Of these groups we found that PsA patients had the greatest increase in OCPs and CD patients had less than normal healthy controls.
2 insert). Thus, osteoclastogenesis in arthritic joints is directly proportional to OCP levels in the peripheral blood. Investigating the mechanisms that regulate the mobilization of myeloid cell precursors in disease conditions, such as RA, will greatly enhance our understanding of why and how there are elevated myeloid precursors in chronic inflammatory diseases and potentially provide novel drug targets for these diseases.
Using OCPs as a Biologic Marker ACKNOWLEDGEMENT
It is likely that blood OCPs have potentially significant clinical impact, namely: 1) the pool size of OCPs likely determines the number of osteoclasts formed in response to locally released osteoclastogenic cytokines and thus the extent of erosion; 2) it is possible that PBMC OCP frequency could be used as a clinical diagnostic to assess risk of bone loss and response to therapy; 3) direct targeting of blood OCPs may represent a novel strategy to prevent or treat osteoclast-mediated bone loss. However, since CD11b + /Gr-1 -/lo cells are common myeloid precursors for macrophages, dendritic cells and osteoclasts and they may increase non-specifically in all chronic inflammatory diseases, the expression profile of specific cytokines within the local micro-environment plays an essential role to determine the fate of these cells. form of osteolysis whose pathogenesis may significantly differ from metabolic bone disorders. In these diseases, the mature osteoclasts actively remove bone and cartilage and die off rapidly after that. At the meantime, the inflammatory tissues continually produce high levels of RANKL and TNF to drive the formation of new osteoclasts from the precursors. As a result, the osteoclast turnover is remarkably increased locally, which is not observed in postmenopausal osteoporosis. Abnormally accelerated osteoclastogenesis requires the body to continuously supply OCPs to the inflammatory sites to fulfill the increased demand for them. Thus, OCP generation in the bone marrow and mobilization among bone marrow, peripheral blood and inflamed joints could play an important role in focal osteolysis in erosive arthritis.
CMP
= Common myeloid progenitors GMP = Granulocyte/macrophage progenitors MODP = Macrophage / osteoclast/dendritic cell progenitors Based on recent pre-clinical and clinical studies, we propose a model for OCP generation and mobilization in erosive arthritis (Fig. 2) . During chronic inflammation, elevated systemic cytokines, such as TNF, induce bone marrow OCP proliferation and stimulate the production of chemokines by cells in the inflamed synovium to form a chemokine gradient between blood and joint, and between diaphysis and subchondral bones near the joints. Increased marrow OCPs are released into the circulation through undefined mechanisms. The blood OCPs home to the joints through a chemtactic effect. Simultaneously, OCPs within the bone marrow migrate to the subchondral bone regions towards the chemokine gradient. Under the influence of local high levels of RANKL and TNF, these OCPs differentiate to mature osteoclasts to cause bone and cartilage damage (Fig. 
